Author

Raffaele Piccolo

h-index 7 View on Semantic Scholar

We have 3 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Pathway-Guided and Patient-Centered Therapeutic Strategies in Atherosclerotic Cardiovascular Disease.

Atherosclerotic cardiovascular disease (ASCVD), encompassing coronary artery disease (CAD), cerebrovascular disease (ischemic stroke, IS; and transient ischemic attack, TIA), and peripheral artery disease (PAD) of atherosclerotic origin, remains a leading cause of morbidity and mortality worldwide despite major advance...

M. Canonico, M. Avvedimento, F. Borrelli et al. · European Journal of Preventi... · 0 citations

Open access Oct 2026

Ticagrelor Monotherapy or Aspirin Plus Prasugrel After Percutaneous Coronary Intervention

Background The 2025 American College of Cardiology/American Heart Association guidelines endorse de-escalation to ticagrelor monotherapy after percutaneous coronary intervention (PCI) for acute coronary syndromes (ACSs), whereas the 2023 European Society of Cardiology guidelines recommend 12-month dual antiplatelet the...

Michele Maremmani, Enrico Citerni, O. de Filippo et al. · JACC: Advances · 0 citations

Aug 2026

De-escalation of antiplatelet therapy to evaluate platelet reactivity and clinical outcomes after coronary stenting in patients at high bleeding risk and recent acute coronary syndrome: Rationale and design of the DESC-HBR trial.

DesC-HBR is the first randomized trial directly comparing multiple P2Y12 inhibitor de-escalation strategies in HBR patients post-ACS and will provide information to guide individualized antiplatelet strategies balancing ischemic protection and bleeding mitigation in HBR patients.

Francesco Costa, G. Vizzari, S. Zecchino et al. · Cardiovascular Revasculariza... · 0 citations